As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Research cut their Q2 2026 earnings estimates for shares of BioMarin Pharmaceutical in a research report issued on Wednesday, March 19th. Zacks Research analyst S. Ganoria now expects that the ...

We recently published a list of Paul Singer’s Latest Portfolio: Top 10 Stock Picks. In this article, we are going to take a ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

EverSource Wealth Advisors LLC lowered its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 91.1% in the ...

On Tuesday, March 4, 2025, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented at the TD Cowen 45th Annual Healthcare Conference. The company outlined its strategic direction, highlighting both ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

BioMarin Pharmaceutical (BMRN) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Studies have ...

The latest update is out from BioMarin Pharmaceutical ( (BMRN)). On February 20, 2025, BioMarin Pharmaceutical’s Board of Directors expanded from eleven to twelve members, appointing Timothy P.